Accumulation of cis-Diamminedichloroplatinum(II) and Platinum Analogues by Platinum-resistant Murine Leukemia Cells in Vitro

Cancer Research

Volumn 48, Issue 1, 1988, Pages 9-13

  Kraker, Alan J ^a   Moore, Charles W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CISPLATIN DERIVATIVE;

ANIMAL CELL; CELL CULTURE; CELL LINE; DRUG ACCUMULATION; DRUG RESISTANCE; LEUKEMIA CELL; MOUSE; NONHUMAN;

ANIMAL; CISPLATIN; DNA; DNA DAMAGE; DRUG RESISTANCE; GLUTATHIONE; LEUKEMIA, EXPERIMENTAL; MICE; PLATINUM; TUMOR CELLS, CULTURED;

EID: 0023882049     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kraker, A. J., Steinkampf, R. W., and Moore, C. W. Transport of cis-Pt and cis-Pt analogs in sensitive and resistant murine leukemia cell lines. Proc. Am. Assoc. Cancer Res., 27:286,1986.
2. Bruchovsky, N., and Goldie, J. H. (eds.). Drug and Hormone Resistance in Neoplasia, Vol. 1. Boca Raton, FL: CRC Press, Inc., 1983.
3. Harris, A. L. Drug resistance to cancer chemotherapy. Drugs Today, 20: 657-663,1984.
4. Fry, D. W., and Jackson, R. C. Membrane transport alterations as a mechanism of resistance to anticancer agents. Cancer Surv., 5: 47-79,1986.
5. Hill, B. T. Biochemical and cell kinetic aspects of drug resistance. In: N. Bruchovsky and J. H. Goldie (eds.), Drug and Hormone Resistance in Neoplasia, Vol. 1, pp. 21–53. Boca Raton, FL: CRC Press, Inc., 1983.
6. Goldenberg, G. J., and Begleiter, A. Alterations of drug transport. In: B. W. Fox and M. Fox (eds.), Handbook of Experimental Pharmacology, Vol. 72, pp. 241–298. Berlin: Springer-Verlag, 1984.
7. Burchenal, J. H., Kalaher, K., O’Toole, T., and Chisholm, J. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res., 37:3455-3457,1977.
8. Burchenal, J. H., Kalaher, K., Dew, K., Lokys, L., and Gale, G. Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives. Biochimie (Paris), 60:961-965,1978.
9. Schabel, F. M., Jr., Trader, M. W., Laster, W. R., Corbett, T. H., and Griswold, D. P. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat. Rep., 63:1459-1473, 1979.
10. Burchenal, J. H., Kalaher, K., O’Toole, T., and Chisholm, J. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res., 37:3455-3457,1977.
11. Richon, V. M., Schulte, N., and Eastman, A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(11) in murine leukemia L1210 cells. Cancer. Res., 47:2056-2061,1987.
12. Andrews, P. A., Murphy, M. P., and Howell, S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res., 45:6250-6253,1985.
13. Frei, E., III, Cucchi, C. A., Rosowsky, A., Tantravahi, R., Bernal, S., Ervin, T. J., Ruprecht, R. M., and Haseltine, W. A. Alkylating agent resistance: in vitro studies with human cell lines. Proc. Natl. Acad. Sci. USA, 82: 2158–2162, 1985.
14. Roberts, J. J., Rawlings, C. J., and Friedlos, F. DNA repair characteristics of Walker rat carcinoma cells sensitive and resistant to cis-diamminedichlo- (cisplatin) and difunctional alkylating agents. In: K. R. Harrap, W. Davis, and A. H. Calvert (eds.), Cancer Chemotherapy and Selective Drug Development, pp. 389–394. The Hague: Martinus Nijhoff, 1984.
15. Zwelling, L. A., Michaels, S., Schwartz, H., Dobson, P. P., and Kohn, K. W. DNA cross-linking as an indicator of sensitivity and resistance of mouse L121L leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res., 41:640-649,1981.
16. Strandberg, M. C. Studies on the resistance of a murine leukemia L1210 cell line to cis-diamminedichloroplatinum(II). Proc. Am. Assoc. Cancer Res., 22: 202, 1981.
17. Strandberg, M. C., Bresnick, E., and Eastman, A. The significance of DNA cross-linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells. Chem. -Biol. Interact., 39:169-180,1982.
18. Hamilton, T. C., Winker, M. A., Louie, K. G., Batist, G., Behrens, B. C., Tsuruo, T., Grotzingle, K. R., McKay, W. M., Young, R. C., and Ozols, R. F. Augmentation of adriamydin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthion-ine sulfoximine mediated glutathione depletion. Biochem. Pharmacol., 34: 2583-2586,1985.
19. Waud, W. R., and Blount, S. R. Biochemical studies on resistance to cis-platinum (cis-DDP) in L1210 leukemia. Proc. Am. Assoc. Cancer Res., 26: 260, 1985.
20. Burchenal, J. H., Kalaher, K., O’Toole, T., and Chisholm, J. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res., 37:3455-3457,1977.
21. Ekhholtz-Wirth, H., and Hktel, B. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br. J. Cancer, 54: 239–243, 1986.
22. Mathe, G., Kidani, Y., Misset, J. L., Triana, K., Machover, D., and Musset, M. Phase 1 trial of oxalato-platinum (L-OHP): a new trial design with dose escalation in each patient. Proc. Am. Assoc. Cancer Res., 27:190,1986.
23. Suzukake, K., Petro, B. J., and Vistka, D. T. Reduction in glutathione content of l-pam resistant L1210 cells confers drug sensitivity. Biochem. Pharmacol., 31:121-124,1982.
24. Minkel, D. T., and Petering, D. H. Initial reaction of 3-ethoxy-2-oxobu-tyraldehyde bis(thiosemicarbazonato)copper(lI) with Ehrlich ascites cells. Cancer Res., 38:117-123,1979.
25. Arrick, B. A., and Nathan, C. F. Glutathione metabolism as a determinant of therapeutk efficacy: a review. Cancer Res., 44:4224-4232,1984.
26. Green, J. A., Vistka, D. T., Young, R. C., Hamilton, T. C., Rogan, A. M., and Ozols, R. F. Potentiation of melphalan cytotoxicity in human ovarian